0 1 7 ) A 3 9 9 -A 8 1 1 A411 version also takes account of other HPV-associated cancers (vaginal, vulvar, anal, penile, and selected oropharyngeal cancers) using an incidence-based approach. Parameter estimates were obtained from various sources including published literature, German cancer registry and claims data. Coverage among boys was assumed to be half the current coverage among girls. For female vaccination, the market shares of the ninevalent and bivalent vaccines were estimated to be 83% and 17%, respectively. The economic analysis was conducted from the societal perspective. Future costs and health effects were discounted at 3% per year. Results: Compared to girls-only vaccination, additional vaccination of boys prevented incremental 22,400 cervical cancer cases and 25,600 non-cervical cancer cases over a 100-year time horizon. Under base case assumptions, ICERs were € 63,200 per QALY gained when excluding the effects on non-cervical cancers and € 26,100 per QALY gained when including them. ConClusions: Considering the commonly cited threshold of € 50,000 per QALY gained, additional HPV vaccination of boys is likely to be cost-effective in Germany when including the impact on non-cervical cancers. ReseaRch PosteR PResentations -session i Disease -sPecific stuDies canceR -clinical outcomes studies Pcn1 LoweR anteRioR Resection suRgicaL comPLications in coLoRectaL canceR Patients: association with Length of stay, DischaRge to institutionaL caRe, anD 90-Day ReaDmission

No abstract